The Effectiveness of Elranatamab in the Management of Refractory Multiple Myeloma with Central Nervous System Involvement

Internal Medicine 2026 Open access

Read full text
Authors: Misaki Uemura, Atsushi Marumo, Atsushi Obata, Nana Matsumoto, Meya Li, Yuta Kaito, Yasunobu Nagata, Satoshi Wakita, Hideto Tamura, Hiroki Yamaguchi
DOI: 10.2169/internalmedicine.6418-25
Cited by: 1
References: 19

Abstract

Multiple myeloma with central nervous system (CNS) involvement is rare and associated with a poor prognosis. Although the emergence of novel therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies, has made it possible to obtain long-term disease control in multiple myeloma, there is still no established standard treatment for cases with CNS involvement, and the efficacy of novel therapies remains unclear. To our knowledge, we herein report the first case of successful elranatamab treatment in Japan in a patient with refractory multiple myeloma showing impaired consciousness caused by CNS involvement.

Fields of Study & Subjects

Multiple Myeloma Research and Treatments CAR-T cell therapy research Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Internal Medicine
Publisher
Japanese Society of Internal Medicine
Volume
65
Issue
16
Pages
2231–2236
Publication date
14 January 2026
Language
EN